Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | F10 | P00742 | 13/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | SDHA | P31040 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833650 | 0.87 | MAOB (0.65) | MAOAF10CYP2E1MAOBLMNA | |
| SCHEMBL5833644 | 0.87 | MAOB (0.65) | MAOAF10CYP2E1MAOBLMNA | |
| SCHEMBL24169998 | 0.87 | MAOA (0.60) | MAOAF10CYP2E1MAOBLMNA | |
| SCHEMBL18410478 | 0.87 | MAOA (0.60) | MAOAF10CYP2E1MAOBLMNA | |
| SCHEMBL13428748 | 0.83 | MAOA (0.52) | MAOAF10CYP2E1MAOBCYP1A2 | |
| SCHEMBL11969777 | 0.83 | MAOA (0.52) | MAOAF10CYP2E1MAOBCYP1A2 | |
| SCHEMBL13428480 | 0.81 | MAOA (0.50) | MAOAF10CYP2E1F2 | |
| SCHEMBL11969006 | 0.81 | MAOA (0.54) | MAOAF10CYP2E1MAOB | |
| SCHEMBL3323196 | 0.81 | MAOA (0.79) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL3323187 | 0.81 | MAOA (0.79) | MAOACYP2E1MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| EP-1121358-A1 | HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS | AstraZeneca AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021960-A1 | HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | MAOA 652/4885F10 1845/4885CYP2E1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.